Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Proteostasis Therapeutics, Inc.    PTI

PROTEOSTASIS THERAPEUTICS, INC.

(PTI)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Proteostasis Therapeutics Up 25%; BlackRock Disclosed 5.9% Stake Friday

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2019 | 03:07pm EDT

By Josh Beckerman

Shares of biopharmaceutical company Proteostasis Therapeutics recently traded up 25.2% to $4.02.

Late Friday, BlackRock disclosed a 5.9% stake in Proteostasis.

In December, Proteostasis announced a licensing agreement with Roche Holding Genentech unit.

Write to Josh Beckerman at josh.beckerman@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
BLACKROCK, INC. -1.25% 445.04 Delayed Quote.13.29%
PROTEOSTASIS THERAPEUTICS, INC. 0.00% 0.73 Delayed Quote.-77.47%
ROCHE HOLDING AG 0.33% 289.35 Delayed Quote.18.88%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PROTEOSTASIS THERAPEUTICS,
10/03PROTEOSTASIS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements..
AQ
09/26PROTEOSTASIS THERAPEUTICS : to Present at the 2019 Cantor Global Healthcare Conf..
PR
09/19PROTEOSTASIS THERAPEUTICS : Announces Presentation at the UK Cystic Fibrosis Con..
PR
08/30PROTEOSTASIS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Co..
AQ
08/07PROTEOSTASIS : 2Q Earnings Snapshot
AQ
08/07PROTEOSTASIS THERAPEUTICS : Management's Discussion and Analysis of Financial Co..
AQ
08/07PROTEOSTASIS THERAPEUTICS, INC. : Results of Operations and Financial Condition,..
AQ
08/07PROTEOSTASIS THERAPEUTICS : Reports Second Quarter 2019 Financial Results and Pr..
PR
08/05PROTEOSTASIS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements..
AQ
07/26PROTEOSTASIS THERAPEUTICS, INC. : Change in Directors or Principal Officers (for..
AQ
More news
Financials (USD)
Sales 2019 5,81 M
EBIT 2019 -79,4 M
Net income 2019 -76,4 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -0,49x
P/E ratio 2020 -0,48x
Capi. / Sales2019 6,42x
Capi. / Sales2020 6,28x
Capitalization 37,3 M
Chart PROTEOSTASIS THERAPEUTICS, INC.
Duration : Period :
Proteostasis Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PROTEOSTASIS THERAPEUTICS,
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 8,50  $
Last Close Price 0,73  $
Spread / Highest target 1 818%
Spread / Average Target 1 064%
Spread / Lowest Target 448%
EPS Revisions
Managers
NameTitle
Meenu Chhabra Karson President, Chief Executive Officer & Director
Michael James Barrett Chairman
Sheila Wilson Chief Operating Officer
Benito Munoz Chief Scientific Officer
Geoffrey S. Gilmartin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
PROTEOSTASIS THERAPEUTICS, INC.-77.47%37
GILEAD SCIENCES3.77%82 611
VERTEX PHARMACEUTICALS7.25%45 680
REGENERON PHARMACEUTICALS-19.63%32 998
WUXI APPTEC CO., LTD.68.13%20 570
GENMAB32.08%13 649